Ranbaxy Pharmaceuticals Inc. To Market Zonisamide Capsules In U.S.

PRINCETON, N.J., June 9 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), of Jacksonville, Florida, a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced plans to market Zonisamide Capsules for the treatment of epilepsy in the U.S. market through a strategic partnership with Invagen Pharmaceuticals Inc. (Invagen) of Hauppauge, New York. Invagen has received U.S. FDA approval for bio-equivalency and, therefore a therapeutically equivalent Zonisamide to the listed drug Zonegran(TM)* Capsules, 25mg, 50mg, and 100mg respectively.